Most prostate cancers respond well to androgen-deprivation
therapy; prostate specific antigen (PSA) levels plummet, tumors
shrink, and symptoms of the disease improve. The response can
last for years but virtually all prostate cancers eventually
escape androgen-deprivation therapy and sharply increasing a man
chances of dying from prostate cancer. A new immunotherapy
option, Provenge (sipuleucel-T) is now available. The new
prostate cancer "vaccine" aims to rev up the body's own
immunologic defense mechanisms so they will target
androgen-independent prostate cancer cells.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.